Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Cash Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Share-Based Liabilities Paid Trading Arrangement: Trading Arrangement [Axis] Long term funding partnership, royalty percentage on annual net sales Long Term Funding Partnership, Royalty Percentage On Annual Net Sales Long Term Funding Partnership, Royalty Percentage On Annual Net Sales Maximum Maximum [Member] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Milestone payments Payments For Milestones Payments For Milestones Statistical Measurement [Domain] Statistical Measurement [Domain] Title of 12(b) Security Title of 12(b) Security Net income attributable to Royalty Pharma plc - diluted Net Income (Loss) Available to Common Stockholders, Diluted Subsequent Event Subsequent Event [Member] Document Fiscal Year Focus Document Fiscal Year Focus Acquisition-related expenses Business Combination, Acquisition-Related Cost, Expense Weighted average coupon rate (as percent) Debt, Weighted Average Interest Rate Adjustment to Compensation, Amount Adjustment to Compensation Amount Financial Instrument [Axis] Financial Instrument [Axis] RP Holdings RP Holdings [Member] RP Holdings Contributions Noncontrolling Interest, Increase From Contributions Noncontrolling Interest, Increase From Contributions Customer [Axis] Customer [Axis] Redemptions, liability Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Redemptions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Redemptions RPCT Royalty Pharma Collection Trust [Member] Royalty Pharma Collection Trust Changes in fair value, liability Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustments Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustments Common stock Common Stock, Value, Issued Summary of Borrowings Schedule of Long-Term Debt Instruments [Table Text Block] Requisite service period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Financial Royalty Assets, Non-current Financial Royalty Assets, Non-current [Member] Financial Royalty Assets, Non-current Cytokinetics Funding Commitments Cytokinetics Funding Commitments [Member] Cytokinetics Funding Commitments Contributions from non-controlling interests - other Proceeds From Noncontrolling Interests, Other Proceeds From Noncontrolling Interests, Other Interest received Proceeds from Interest Received Restatement Determination Date Restatement Determination Date Exchange Offer Transaction Exchange Offer Transaction [Member] Exchange Offer Transaction Old RPI Royalty Pharma Investments (Old RPI) [Member] Royalty Pharma Investments (Old RPI) $600,000, 2.15% (issued at 98.263% of par) Two Point One Five Percent Senior Notes Due 2031 [Member] Two Point One Five Percent Senior Notes Due 2031 Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets Financing Receivable, Change In Present Value, Increases To Cumulative Allowance Financing Receivable, Change in Present Value, Increases To Cumulative Allowance Research and development commitment Research and Development Commitment Research and Development Commitment Measurement Frequency [Axis] Measurement Frequency [Axis] The Notes The Notes [Member] The Notes Financial Royalty Assets Financing Receivables [Text Block] Distributions payable to non-controlling interests Total distributions payable to non-controlling interests Distributions Payable To Non-Controlling Interests, Current Distributions Payable To Non-Controlling Interests, Current Royalty Pharma Investments Royalty Pharma Investments [Member] Royalty Pharma Investments Amendment Flag Amendment Flag Current liabilities Liabilities, Current [Abstract] Debt and Equity Securities, FV-NI [Line Items] Debt and Equity Securities, FV-NI [Line Items] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Property, plant and equipment Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment Other royalty income receivable Increase (Decrease) In Other Royalty Income Receivable Increase (Decrease) In Other Royalty Income Receivable Subject to Vesting Subject To Vesting [Member] Subject To Vesting Changes in fair value, asset Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Fair Value Adjustments Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Fair Value Adjustments Shares and share-based awards issued for Internalization Internalization Stock Issued During Period, Value, Acquisitions Related Party Transactions Related Party Transactions Disclosure [Text Block] Distributions to continuing non-controlling interests Payments to Noncontrolling Interests Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Entity Address, State or Province Entity Address, State or Province PEO Total Compensation Amount PEO Total Compensation Amount Long term funding partnership, royalty installment repayments, amount Long Term Funding Partnership, Royalty Installment Repayments, Amount Long Term Funding Partnership, Royalty Installment Repayments, Amount Common stock, par value (in dollars/pounds per share) Common Stock, Par or Stated Value Per Share Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Cystic fibrosis franchise Cystic Fibrosis Franchise [Member] Cystic Fibrosis Franchise Assets: Assets, Fair Value Disclosure [Abstract] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Basic (in shares) Weighted average Class A ordinary shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Summary of Related Party Transactions Schedule of Related Party Transactions [Table Text Block] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Losses on available for sale debt securities Losses on available for sale debt securities Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Development-stage funding payments Payments For Development Stage Funding Payments For Development Stage Funding Number of reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current Tranches One, Four, Five And Six Tranches One, Four, Five And Six [Member] Tranches One, Four, Five And Six Maximum consolidated leverage ratio following qualifying material acquisition Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition Long term funding partnership, number of tranches Long Term Funding Partnership, Number Of Tranches Long Term Funding Partnership, Number Of Tranches Entity Address, City or Town Entity Address, City or Town Employee EPAs Deferred Compensation Share-Based Arrangement Liability, Awards Settled During Period Deferred Compensation Share-Based Arrangement Liability, Awards Settled During Period Summary of Cash Flow, Supplemental Disclosures Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Proceeds from equity securities Proceeds Equity Securities Proceeds Equity Securities Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Receivables [Abstract] Statement of Financial Position [Abstract] Title and Position [Domain] Title and Position [Domain] Document Information [Line Items] Document Information [Line Items] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Basis of Preparation Basis of Accounting, Policy [Policy Text Block] Class of Stock [Axis] Class of Stock [Axis] JNJ‑4804 JNJ-4804 [Member] JNJ-4804 Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Distributions from equity method investees Proceeds from Equity Method Investment, Distribution, Return of Capital Net income attributable to Royalty Pharma plc - basic Net Income (Loss) Available to Common Stockholders, Basic Avillion II Avillion II [Member] Avillion II Level 2 Fair Value, Inputs, Level 2 [Member] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Share exchange basis Share Exchange Basis Share Exchange Basis Line of credit, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Current portion of long-term debt Less: Current portion of long-term debt Long-Term Debt, Current Maturities Proceeds from sales of available for sale debt securities Proceeds from Additional Sales of Available for Sale Debt Securities Proceeds from Additional Sales of Available for Sale Debt Securities Subsequent Event Type [Axis] Subsequent Event Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Phase 3 Trial Phase 3 Trial [Member] Phase 3 Trial 2020 Equity Incentive Plan 2020 Equity Incentive Plan [Member] 2020 Equity Incentive Plan Recently Adopted and Issued Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Total non-current assets Assets, Fair Value Disclosure, NonCurrent Assets, Fair Value Disclosure, NonCurrent Remaining aggregate amount subject to vesting Share-Based Compensation Arrangement By Share-Based Payment Award, Remaining Amount Subject To Vesting Share-Based Compensation Arrangement By Share-Based Payment Award, Remaining Amount Subject To Vesting Non-Controlling Interests Noncontrolling Interest [Member] Use of Estimates Use of Estimates, Policy [Policy Text Block] Related Party [Axis] Related and Nonrelated Parties [Axis] Unsecured Debt Unsecured Debt [Member] R&D funding expense, accrued portion Research and Development, Accrued Liability, Current Research and Development, Accrued Liability, Current Total debt carrying value Long-term debt, carrying value Long-Term Debt Maximum consolidated cash flow ratio Debt Instrument, Covenant Terms, Maximum Consolidated Cash Flow Ratio Debt Instrument, Covenant Terms, Maximum Consolidated Cash Flow Ratio Document Period End Date Document Period End Date Number of tranches available for draw Long Term Funding Partnership, Number Of Tranches Available For Draw Long Term Funding Partnership, Number Of Tranches Available For Draw Net cash (used in)/provided by investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Debt issued, amount Debt Instrument, Face Amount Earnings per Class A ordinary share: Earnings Per Share, Basic [Abstract] Security Exchange Name Security Exchange Name Term Loan Business Combination, Recognized Liability Assumed, Long-Term Debt, Noncurrent Treasury interests Treasury Stock, Common, Value Weighted average effective interest rate (as percent) Debt Instrument, Interest Rate, Effective Percentage Financing receivable, unapproved financial assets held at cost Financing Receivable, Unapproved Financial Assets Held At Cost Financing Receivable, Unapproved Financial Assets Held At Cost Long term funding partnership, remaining availability Long Term Funding Partnership, Remaining Availability Long Term Funding Partnership, Remaining Availability Gross Carrying Value Financing Receivable, before Allowance for Credit Loss Indirect Cash Flow Cash Flow, Supplemental Disclosures [Text Block] Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets Financing Receivable, Change In Present Value, Decreases To Cumulative Allowance, Reversal Of Expense Financing Receivable, Change In Present Value, Decreases To Cumulative Allowance, Reversal Of Expense Entity Shell Company Entity Shell Company Class B Ordinary Shares Common Class B [Member] Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized $500,000, 5.15% (issued at 98.758% of par) Five Point One Five Percent Senior Notes Due 2029 [Member] Five Point One Five Percent Senior Notes Due 2029 Interest payable Interest Payable, Current Segment Information Segment Reporting, Policy [Policy Text Block] Earnings per Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Earnings Per Share [Abstract] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Total liabilities Liabilities Trading Symbol Trading Symbol Measurement Input, Discount Rate Measurement Input, Discount Rate [Member] Class R Redeemable Shares Class R Redeemable Stock [Member] Class R Redeemable Stock Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Denominator Weighted Average Number of Shares Outstanding, Basic [Abstract] Summary of Preliminary Allocation of Purchase Price Business Combination, Recognized Asset Acquired and Liability Assumed [Table Text Block] Company Selected Measure Name Company Selected Measure Name Sale of Stock [Domain] Sale of Stock [Domain] Purchases of available for sale debt securities Payments to Acquire Debt Securities, Available-for-Sale Amortization of debt discount and issuance costs Amortization of Debt Issuance Costs and Discounts Financial royalty assets Financing Receivable, after Allowance for Credit Loss, Current Acquisitions of financial royalty assets Aggregate royalty interest payments Payments to Acquire Finance Receivables Overnight Bank Funding Rate Overnight Bank Funding Rate [Member] Overnight Bank Funding Rate Ownership percentage (as a percent) Subsidiary, Ownership Percentage, Parent Total Long-Term Debt, Gross Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Phase 2b, TEV-408 Phase 2b, TEV-408 [Member] Phase 2b, TEV-408 Available for sale debt securities Debt Securities Debt Securities [Member] Credit Facility [Domain] Credit Facility [Domain] Asset Class [Domain] Asset Class [Domain] Related Party Transactions [Abstract] Cash flows from operating activities: Cash flow from operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Diluted (in shares) Weighted average Class A ordinary shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Dividends (in dollars per share) Dividends paid (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Acquisition costs incurred, percentage Business Combination, Cost Incurred, Percentage Business Combination, Cost Incurred, Percentage Credit Loss [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Continuing Investors Partnerships Continuing Investors Partnerships [Member] Continuing Investors Partnerships Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Fair value of EPAs Deferred Compensation Share-Based Arrangements, Liability, Classified, Noncurrent Other assets Increase (Decrease) in Other Noncurrent Assets Royalty Pharma plc Royalty Pharma plc [Member] Royalty Pharma plc Distributions to legacy non-controlling interests - Portfolio Receipts Payments To Noncontrolling Interests, Portfolio Receipts Payments To Noncontrolling Interests, Portfolio Receipts Summary of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Continuing Investors Partnerships Continuing Investors Partnership [Member] Continuing Investors Partnership Writeoff related to financial royalty asset Financing Receivable, Allowance for Credit Loss, Financial Royalty Asset, Writeoff Financing Receivable, Financial Royalty Asset, Writeoff Award Timing Predetermined Award Timing Predetermined [Flag] Treasury Interests Treasury Stock, Common [Member] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Level 1 Fair Value, Inputs, Level 1 [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Lease payments, minimum amount Lessee, Operating Lease, Liability, to be Paid Income from financial royalty assets Financial Royalty Assets [Member] Financial Royalty Assets The Notes and Term Loan The Notes and Term Loan [Member] The Notes and Term Loan Unvested RSUs (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Recognized liability assumed Business Combination, Recognized Liability Assumed, Financial Liability Number of consecutive quarterly payments Number Of Consecutive Quarterly Payments Number Of Consecutive Quarterly Payments Evrysdi Evrysdi [Member] Evrysdi Deferred Shares Deferred Shares Deferred Shares [Member] Deferred Shares All Executive Categories All Executive Categories [Member] Mr. Legorreta Chief Executive Officer [Member] Repurchases of Class A ordinary shares Stock repurchased and retired value during the period Stock Repurchased and Retired During Period, Value Former Operating and Personnel Payments Former Operating And Personnel Payments [Member] Former Operating And Personnel Payments Pre-Internalization Pre-Internalization [Member] Pre-Internalization Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Assumed exchanges of Class B ordinary shares (in shares) Incremental Common Shares Attributable To Dilutive Effect Of Exchangeable Shares Incremental Common Shares Attributable To Dilutive Effect Of Exchangeable Shares Fair value of outstanding notes Long-Term Debt, Fair Value Depreciation Depreciation Number of noncontrolling interests created Number Of Noncontrolling Interests Created Number Of Noncontrolling Interests Created Plan Name [Domain] Plan Name [Domain] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Vested (in shares) Equity, Vested, Number Of Shares Equity, Vested, Number Of Shares Summary of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Total purchase price Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill Fair Value Disclosures [Abstract] Debt Disclosure [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Royalty at Fair Value Royalty [Member] Share-based compensation and share issuances for EPAs, Equity Incentive Plans and forfeiture of shares issued for Internalization Stock Issued During Period, Value, Employee Benefit Plan Available for Sale Debt Securities Investment in Debt and Equity Securities and Other Trading Assets [Text Block] Minimum Minimum [Member] Collaborative arrangement, funded amount Collaborative Arrangement Rights And Obligations, Funded Amount Collaborative Arrangement Rights And Obligations, Funded Amount Expiration Date Trading Arrangement Expiration Date 2030 Long-Term Debt, Maturity, Year Four Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Weighted average Class A ordinary shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Cytokinetics Cytokinetics [Member] Cytokinetics Summary of Deferred Compensation Share-Based Payment Liability Disclosure Of Deferred Compensation Share-Based Payment Liability [Table Text Block] Disclosure Of Deferred Compensation Share-Based Payment Liability Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Money market funds Cash and Cash Equivalents, Fair Value Disclosure Total shareholders’ equity Beginning balance Ending balance Cumulative adjustment to retained earnings Equity, Including Portion Attributable to Noncontrolling Interest Trelegy Trelegy [Member] Trelegy Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Business Combination [Line Items] Business Combination [Line Items] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Other (income)/expense Other Income and Expenses [Abstract] Quarterly payments to affiliates, percent of security investment (as percent) Rate, Value Of Security Investments Rate, Value Of Security Investments Purchases of equity securities Payments To Acquire Equity Securities, FN-NI Payments To Acquire Equity Securities, FN-NI Exercise Price Award Exercise Price Cash flows from investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Related Party Transaction [Axis] Related Party Transaction [Axis] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Fair Value, Recurring Fair Value, Recurring [Member] Stock repurchase program, authorized repurchase amount Share Repurchase Program, Authorized, Amount Number of quarters Long Term Funding Partnership, Number Of Quarters Long Term Funding Partnership, Number Of Quarters Pro forma net income Business Combination, Pro Forma Information, Pro Forma Income (Loss), after Tax $700,000, 3.35% (issued at 97.565% of par) Three Point Three Five Percent Due 2051 [Member] Three Point Three Five Percent Due 2051 Recognized amount Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Quarterly Report Document Quarterly Report Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Accounting Standards Update [Extensible Enumeration] Accounting Standards Update [Extensible Enumeration] 2020 Notes 2020 Notes [Member] 2020 Notes Operating lease right of use asset Business Combination, Recognized Asset Acquired, Operating Lease Right of Use Asset Business Combination, Recognized Asset Acquired, Operating Lease Right of Use Asset Upfront payment to acquire royalties Research and Development, Acquisition of Royalties, Upfront Payment Research and Development, Acquisition of Royalties, Upfront Payment Proceeds from available for sale debt securities Proceeds from Sale of Debt Securities, Available-for-Sale Borrowings Debt Disclosure [Text Block] Proceeds from revolving credit facility Repayments of Long-Term Debt Total current and non-current financial royalty assets, net Total current and non-current financial royalty assets, net Financing Receivable, after Allowance for Credit Loss Debt issuances costs capitalized Debt Issuance Costs, Net Unamortized discount and loan issuance costs on long-term debt Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Uncommitted Credit Facility Uncommitted Credit Facility [Member] Uncommitted Credit Facility Equity method investments Equity Method Investments Business Combination [Table] Business Combination [Table] Equity Component [Domain] Equity Component [Domain] Shareholders' Equity Shareholders' Equity [Text Block] Shareholders' Equity PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Funding commitment remained unfunded Long Term Funding Partnership, Remaining Unfunded Amount Long Term Funding Partnership, Remaining Unfunded Amount Measurement Input Type [Domain] Measurement Input Type [Domain] Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Marshall Urist [Member] Marshall Urist Amortization of prepaid expenses Amortization of Prepaid Expenses Amortization of Prepaid Expenses Exchange offering, ownership percentage (as a percent) Sale of Stock, Percentage of Ownership before Transaction Total operating expense, net Costs and Expenses Adoption Date Trading Arrangement Adoption Date Reclassification from allowance for credit losses on unfunded commitments upon funding Financing Receivable, Allowance for Credit Loss, Reclassification Adjustment Financing Receivable, Allowance for Credit Loss, Reclassification Adjustment Debt instrument, stated rate (as percent) Debt Instrument, Interest Rate, Stated Percentage Counterparty Name [Domain] Counterparty Name [Domain] Dividends declared and paid Dividends, Common Stock, Cash Total other expense, net Nonoperating Income (Expense) Senior Unsecured Revolving Credit Facility And Term Loan Senior Unsecured Revolving Credit Facility And Term Loan [Member] Senior Unsecured Revolving Credit Facility And Term Loan Other assets Business Combination, Recognized Asset Acquired, Other Asset, Noncurrent Senior Unsecured Revolving Credit Facility Senior Unsecured Revolving Credit Facility [Member] Senior Unsecured Revolving Credit Facility Unapproved Assets Unapproved Assets [Member] Unapproved Assets Assets Assets [Abstract] Debt issued as a percent of par value (as percent) Debt Instrument, Issuance As A Percent Of Par Debt Instrument, Issuance As A Percent Of Par Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount $1,000,000, 3.55% (issued at 95.306% of par) Three Point Five Five Percent Senior Notes Due 2050 [Member] Three Point Five Five Percent Senior Notes Due 2050 Unfunded Commitments Research And Development Unfunded Commitments Research And Development Unfunded Commitments Number of equity shares issued (in shares) Business Combination, Consideration Transferred, Equity Interest, Share Issued, Number of Shares Accounting Policies [Abstract] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] TEV-408 TEV-408 [Member] TEV-408 Accrued compensation liabilities Accounts Payable and Accrued Liabilities, Noncurrent Insider Trading Policies and Procedures [Line Items] Other Proceeds from (Payment for) Other Financing Activity Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Minimum consolidated coverage ratio Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio Johnson & Johnson Johnson And Johnson [Member] Johnson And Johnson Operating and personnel payments incurred Selling, General and Administrative Expense Number of votes per share Common Stock, Voting Rights, Number Of Votes Common Stock, Voting Rights, Number Of Votes Business Combination [Domain] Business Combination [Domain] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Number of operating segments Number of Operating Segments Employee RSUs Restricted Stock Units (RSUs) [Member] Entity Central Index Key Entity Central Index Key Cytokinetics Funding Commitments Financial Liabilities, Fair Value Disclosure, NonCurrent Financial Liabilities, Fair Value Disclosure, NonCurrent All Adjustments to Compensation All Adjustments to Compensation [Member] Business Combination [Axis] Business Combination [Axis] Equity [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Net cash provided by operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Maximum consolidated leverage ratio Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio Remainder of 2026 Long-Term Debt, Maturity, Remainder of Fiscal Year Other exchanges Stockholders' Equity, Other 2025 Equity Incentive Plan 2025 Equity Incentive Plan [Member] 2025 Equity Incentive Plan Income Statement [Abstract] Shareholders’ equity Equity, Attributable to Parent [Abstract] Document Transition Report Document Transition Report Funding Commitments Funding Commitments [Member] Funding Commitments Ownership [Axis] Ownership [Axis] Write-off of cumulative allowance Financing Receivable Change In Present Value, Write-Off Cumulative Allowance Financing Receivable Change In Present Value, Write-Off Cumulative Allowance Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Financing receivables, fair value disclosure, non-current Financing Receivables, Fair Value Disclosure, Non-Current Financing Receivables, Fair Value Disclosure, Non-Current Investment, Name [Axis] Investment, Name [Axis] Operating expense/(income) Operating Expenses [Abstract] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Basis spread on variable rate (as percent) Debt Instrument, Basis Spread on Variable Rate Tranche Two Tranche Two [Member] Tranche Two Other current assets Business Combination, Recognized Asset Acquired, Other Asset, Current Deferred stock, par value (in dollars per share) Deferred Shares, Par Or Stated Value Per Share Deferred Shares, Par Or Stated Value Per Share Other Commitments [Domain] Other Commitments [Domain] City Area Code City Area Code Variable Rate [Domain] Variable Rate [Domain] Prior to the applicable par call date Debt Instrument, Redemption, Period One [Member] AOCI Attributable to Parent AOCI Attributable to Parent [Member] Document Information [Table] Document Information [Table] All Individuals All Individuals [Member] Subsequent Event Subsequent Events [Text Block] Redeemable stock, redemption price (in pound per share) Redeemable Stock, Redemption Price Per Share Redeemable Stock, Redemption Price Per Share Tranche 7 Tranche Seven [Member] Tranche Seven Name Forgone Recovery, Individual Name Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Measurement Input, Option Volatility Measurement Input, Option Volatility [Member] Research and Development [Abstract] Weighted average period (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Number of parts to funding arrangement Number Of Parts To Funding Arrangement Number Of Parts To Funding Arrangement Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Dividends to shareholders Payment Of Dividends To Shareholders Payment Of Dividends To Shareholders Internalization, fair value Fair value of equity attributable to pre-Internalization service period: Business Combination, Consideration Transferred, Equity Interest Statement [Line Items] Statement [Line Items] Total assets Assets Entity [Domain] Entity [Domain] Employee and Director RSUs Employee And Director Restricted Stock Units [Member] Employee And Director Restricted Stock Units Quarterly payments to affiliates, percent of adjusted cash receipts (as percent) Rate, Adjusted Cash Receipts Rate, Adjusted Cash Receipts Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Research and Development, Contract to Perform for Others [Table] Milestone payment received Milestone Payment Milestone Payment Interest expense Interest Expense, Nonoperating Share-Based Compensation Share-Based Payment Arrangement [Text Block] Contributions from legacy non-controlling interests - R&D Proceeds From Noncontrolling Interests, Research And Development Proceeds From Noncontrolling Interests, Research And Development Operating lease liabilities Business Combination, Recognized Liability Assumed, Lease Obligation $900,000, 5.20% (issued at 97.989% of par) Five Point Two Zero Percent Senior Notes Due 2035 [Member] Five Point Two Zero Percent Senior Notes Due 2035 PEO PEO [Member] Beginning balance (in shares) Ending balance (in shares) Shares, outstanding (in shares) Shares, Outstanding 2028 Long-Term Debt, Maturity, Year Two Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets Credit Loss, Financial Instrument [Text Block] Share-based compensation expense Total Share-Based Compensation Share-Based Payment Arrangement, Expense Voranigo Voranigo [Member] Voranigo Measurement Basis [Axis] Measurement Basis [Axis] Repurchases of Class A ordinary shares (in shares) Stock repurchased and retired during period (in shares) Stock Repurchased and Retired During Period, Shares Other liabilities Other Liabilities, Noncurrent Goodwill Goodwill Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Financial royalty assets, net Financing Receivable, after Allowance for Credit Loss, Noncurrent Development Funding Development Funding [Member] Development Funding Subsequent Event Type [Domain] Subsequent Event Type [Domain] Credit loss allowance Credit Loss Allowance Credit Loss Allowance Retained Earnings Retained Earnings [Member] Revolving Credit Facility Revolving Credit Facility [Member] Money market funds Money Market Funds [Member] Revision of Prior Period [Domain] Revision of Prior Period [Domain] Distributions from equity method investees Proceeds from Equity Method Investment Proceeds from Equity Method Investment 2024 Notes 2024 Notes [Member] 2024 Notes Cash and cash equivalents Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Common stock, outstanding (in shares) Common shares outstanding (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Debt issuance costs and other Payments of Debt Issuance Costs Financing Receivable, Past Due [Line Items] Financing Receivable, Past Due [Line Items] Diluted (in dollars per share) Earnings per Class A ordinary share - diluted (in dollars per share) Earnings Per Share, Diluted Maximum consolidated cash flow ratio, following qualifying material acquisition Debt Instrument, Covenant Terms, Maximum Consolidated Cash Flow Ratio, Following Qualifying Material Acquisition Debt Instrument, Covenant Terms, Maximum Consolidated Cash Flow Ratio, Following Qualifying Material Acquisition Entity Current Reporting Status Entity Current Reporting Status Net cash used in financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Total Shareholder Return Amount Total Shareholder Return Amount Current period provision for credit losses, net Financing Receivable, Credit Loss, Expense (Reversal) Liabilities: Liabilities, Fair Value Disclosure [Abstract] MorphoSys MorphoSys [Member] MorphoSys Percentage of net economic profit Share Based Compensation Arrangement By Share Based Payment Award, Covenant, Percentage of Net Economic Profit Share Based Compensation Arrangement By Share Based Payment Award, Covenant, Percentage of Net Economic Profit Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Total Awards Earned Awards Earned Summary of Total Purchase Consideration Business Combination [Table Text Block] Ownership [Domain] Ownership [Domain] Summary of Pro Forma Information Business Combination, Pro Forma Information [Table Text Block] Research and development funding expense Research and Development Expense Adjustments to reconcile consolidated net income to net cash provided by operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] 2029 Long-Term Debt, Maturity, Year Three Current Portion of Financial Royalty Assets Financing Receivable [Member] Installment repayments, percentage of amount drawn Long Term Funding Partnership, Installment Repayments, Amount Drawn, Multiple Long Term Funding Partnership, Installment Repayments, Amount Drawn, Multiple RP Holdings Class E Interests Holders RP Holdings Class E Interests RP Holdings Class E Interests Holders [Member] RP Holdings Class E Interests Holders Long-term Purchase Commitment [Line Items] Long-Term Purchase Commitment [Line Items] Share-Based Payment Arrangement [Abstract] Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Upon occurrence of a change of control triggering event Debt Instrument, Redemption, Period Three [Member] Summary of Balance of Non-controlling Interests Schedule of Stockholders Equity [Table Text Block] Financial Instruments [Domain] Financial Instruments [Domain] $500,000, 5.40% (issued at 97.872% of par) Five Point Four Zero Percent Senior Notes Due 2034 [Member] Five Point Four Zero Percent Senior Notes Due 2034 Summary of Equity in Earnings and Distributions of Equity Method Investees Equity Method Investments [Table Text Block] Beginning balance Ending balance Financing Receivable, Allowance for Credit Loss Numerator Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Quarterly conversion basis (in shares) Common Stock, Quarterly Conversion Basis Common Stock, Quarterly Conversion Basis Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Underlying Securities Award Underlying Securities Amount Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] AstraZeneca AstraZeneca [Member] AstraZeneca Interest payable Increase (Decrease) in Interest Payable, Net Sales Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales Cash collected on financial royalty assets Increase (Decrease) In Cash Collections On Financing Receivables Increase (Decrease) In Cash Collections On Financing Receivables Avillion I Avillion I [Member] Avillion I Tranches One, Four, Five, Six, And Seven Tranches One, Four, Five, Six, And Seven [Member] Tranches One, Four, Five, Six, And Seven Other Other Financial Royalty Asset [Member] Other Financial Royalty Asset Other current liabilities Increase (Decrease) in Other Current Liabilities Other Payment for (Proceeds from) Other Investing Activity Cash collections from intangible royalty assets Proceeds From Cash Collections From Royalties Received On Intangible Assets Proceeds From Cash Collections From Royalties Received On Intangible Assets Shares and share-based awards issued for Internalization (in shares) Stock Issued During Period, Shares, Acquisitions Summary of Repayments of Debt by Year Schedule of Maturities of Long-Term Debt [Table Text Block] Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Table] Schedule of Equity Method Investments [Table] Equity Method Investment [Table] Other royalty income and revenues Royalty Income, Other [Member] Royalty Income, Other Title and Position [Axis] Title and Position [Axis] Sale of Stock [Axis] Sale of Stock [Axis] Provision for changes in expected cash flows from financial royalty assets Provision for changes in expected cash flows from financial royalty assets Provision for Other Credit Losses Other current assets Other Assets, Current Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Balance at the beginning of the period Balance at the end of the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Operating income Operating Income (Loss) Current Fiscal Year End Date Current Fiscal Year End Date Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Shares subject to vesting (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Subject To Vesting, Number Share-Based Compensation Arrangement By Share-Based Payment Award, Subject To Vesting, Number Related Party Transaction [Domain] Related Party Transaction [Domain] Internalization Business Combination [Text Block] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Operating lease liabilities, current Business Combination, Recognized Liability Assumed, Lease Obligation, Current Business Combination, Recognized Liability Assumed, Lease Obligation, Current Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Equity Securities Equity Securities [Member] Distributions Distributions Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Portfolio investment period Portfolio Investment Period Portfolio Investment Period Provision for credit losses on unfunded commitments Provision for Credit Losses on Unfunded Commitments Provision for Credit Losses on Unfunded Commitments Financial royalty asset impairment Non-cash impairment charges Asset, Impairment Loss Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Schedule of Cumulative Allowance for Changes in Expected Cash Flows Financing Receivable, Allowance for Credit Loss [Table Text Block] Common stock, issued (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] Non-Consolidated Affiliates Equity Method Investments and Joint Ventures Disclosure [Text Block] Balance at the beginning of the period Balance at the end of the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Transaction value Business Combination, Transaction Value Business Combination, Transaction Value Revolution Medicines, Inc Revolution Medicines, Inc [Member] Revolution Medicines, Inc Gain (losses) on equity securities still held Fair Value, Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) Future draw amount Debt Securities, Available-For-Sale, Future Draw Amount Debt Securities, Available-For-Sale, Future Draw Amount Available for sale debt securities Debt Securities, Available-for-Sale, Current Equity Components [Axis] Equity Components [Axis] Shares contingently issuable attributable to EPA Vehicle (in shares) Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares Related Party Related Party [Member] Product and Service [Domain] Product and Service [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Senior Secured Term Loan Senior Secured Term Loan [Member] Senior Secured Term Loan Class A Ordinary Shares Common Class A [Member] Entity Interactive Data Current Entity Interactive Data Current Variable Rate [Axis] Variable Rate [Axis] Net income attributable to non-controlling interests Less: net income/(loss) attributable to non-controlling interests Net Income (Loss) Attributable to Noncontrolling Interest Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Entity Small Business Entity Small Business Unamortized debt discount and issuance costs Debt Instrument, Unamortized Discount Financing receivables, fair value disclosure, current Financing Receivables, Fair Value Disclosure, Current Financing Receivables, Fair Value Disclosure, Current Termination Date Trading Arrangement Termination Date Net Carrying Value Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows Other Commitments [Axis] Other Commitments [Axis] Noncontrolling Interest [Table] Noncontrolling Interest [Table] Subsequent Events [Abstract] Settlement of forward Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Long term funding partnership, tranches no longer available Debt Securities, Available-For-Sale, Number Of Tranches No Longer Available Debt Securities, Available-For-Sale, Number Of Tranches No Longer Available MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Other current liabilities Other Liabilities, Current Other assets Other Assets, Noncurrent Document Type Document Type Acquisition of businesses, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash collections from financial royalty assets Proceeds From Cash Collections From Royalties Received On Financing Receivables Proceeds From Cash Collections From Royalties Received On Financing Receivables Fair Value as of Grant Date Award Grant Date Fair Value Award Description [Axis] Award Description [Axis] Award Description Redemption price (as percent) Debt Instrument, Redemption Price, Percentage Long term funding partnership, amount Long Term Funding Partnership, Amount Long Term Funding Partnership, Amount Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table] Financial Royalty Asset, Fexalimab Financial Royalty Asset, Fexalimab [Member] Financial Royalty Asset, Fexalimab Financial Royalty Assets, Current Financial Royalty Assets, Current [Member] Financial Royalty Assets, Current Deferred shares, $0.000001 par value; issued and outstanding: 2026–430,189 and 2025–411,475 Deferred Shares, Value, Issued Deferred Shares, Value, Issued Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Share repurchase program, remaining authorized, amount Share Repurchase Program, Remaining Authorized, Amount Arrangement Duration Trading Arrangement Duration Subsequent Event [Line Items] Subsequent Event [Line Items] Statement of Stockholders' Equity [Abstract] Total non-current liabilities Liabilities, Fair Value Disclosure, NonCurrent Liabilities, Fair Value Disclosure, NonCurrent Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Local Phone Number Local Phone Number Vertex Vertex [Member] Vertex Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Changes in operating assets and liabilities: Increase (Decrease) in Operating Assets [Abstract] Other exchanges (in shares) Stockholders' Equity, Other Shares Consolidated net income before tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Commitments and contingencies Commitments and Contingencies Total income and other revenues Revenues Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Equity in earnings of equity method investees Equity in earnings of equity method investees Income (Loss) from Equity Method Investments Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounting Standards Update and Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Equity, Attributable to Noncontrolling Interest [Roll Forward] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Executive Category: Executive Category [Axis] Neurimmune AG Neurimmune AG [Member] Neurimmune AG Long-term Purchase Commitment [Table] Long-Term Purchase Commitment [Table] Award vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Counterparty Name [Axis] Counterparty Name [Axis] Liabilities and shareholders’ equity Liabilities and Equity [Abstract] Number of quarterly cash dividends Number Of Quarterly Cash Dividends Number Of Quarterly Cash Dividends Summary of Fair Value Hierarchy Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Award Type [Domain] Award Type [Domain] Founder’s Equity Founder’s Equity Payable to Founder Founder's Equity [Member] Founder's Equity Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount $500,000, 5.90% (issued at 97.617% of par) Five Point Nine Zero Percent Senior Notes Due 2054 [Member] Five Point Nine Zero Percent Senior Notes Due 2054 Total Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Paid And Payable Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Paid And Payable Fair Value Measurements and Financial Instruments Fair Value Disclosures [Text Block] Deferred stock, outstanding (in shares) Deferred Shares, Shares, Outstanding Deferred Shares, Shares, Outstanding Level 3 Fair Value, Inputs, Level 3 [Member] Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Share-Based Liabilities Paid And Payable In Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Share-Based Liabilities Paid And Payable In Shares $500,000, 5.95% (issued at 95.824% of par) Five Point Nine Five Percent Senior Notes Due 2055 [Member] Five Point Nine Five Percent Senior Notes Due 2055 Stock price (in dollars per share) Share Price Noncontrolling interest (as percent) Subsidiary, Ownership Percentage, Noncontrolling Owner PEO Name PEO Name RP Manager RP Manager [Member] RP Manager Aggregate value Business Combination, Consideration Transferred, Equity Interest, Share Issued, Value Concentrations of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Legal Entity [Axis] Legal Entity [Axis] Available for sale debt securities Debt Securities, Available-for-Sale, Noncurrent Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Thereafter Long-Term Debt, Maturity, After Year Four Long-Term Debt, Maturity, After Year Four Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Tysabri Tysabri [Member] Tysabri Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Long Term Funding Partnership, Tranche [Axis] Long Term Funding Partnership, Tranche [Axis] Long Term Funding Partnership, Tranche Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Financing Receivable, Allowance for Credit Loss [Roll Forward] Financing Receivable, Allowance for Credit Loss [Roll Forward] Revolution Medicines Funding Commitments Revolution Medicines Funding Commitments [Member] Revolution Medicines Funding Commitments Tranche 3 Tranche Three [Member] Tranche Three Organization and Purpose Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Subsequent Event [Table] Subsequent Event [Table] Share-based compensation Share-Based Payment Arrangement, Noncash Expense Other liabilities Business Combination, Recognized Liability Assumed, Other Liability, Noncurrent Cash Payments to Acquire Businesses, Gross Dividends Dividends, Cash Allowance for Credit Loss Credit Loss, Financial Instrument [Policy Text Block] Investment, Name [Domain] Investment, Name [Domain] Customer [Domain] Customer [Domain] 2027 Long-Term Debt, Maturity, Year One Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Basic (in dollars per share) Earnings per Class A ordinary share - basic (in dollars per share) Earnings Per Share, Basic Measurement Input Type [Axis] Measurement Input Type [Axis] Summary of Share-Based Compensation Expense Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Repurchases of Class A ordinary shares Payments for Repurchase of Common Stock Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Insider Trading Arrangements [Line Items] Cumulative Allowance for Changes in Expected Cash Flows (Note 9) Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows Long-term debt Total long-term debt Long-Term Debt, Excluding Current Maturities Award Type [Axis] Award Type [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Retained earnings Retained Earnings (Accumulated Deficit) Product and Service [Axis] Product and Service [Axis] Award Description [Domain] Award Description [Domain] Award Description [Domain] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Common Stock Common Stock [Member] Financial royalty asset, percentage of non-controlling interest Financial Royalty Asset Percentage Of Non-controlling Interest Financial Royalty Asset Percentage Of Non-controlling Interest Fair Value Measurement [Domain] Fair Value Measurement [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Total Commitments Research And Development Commitments Research And Development Commitments Cover [Abstract] $1,000,000, 1.75% (issued at 98.284% of par) One Point Seven Five Percent Senior Notes Due 2027 [Member] One Point Seven Five Percent Senior Notes Due 2027 Aggregate royalty interest payments, upfront payment Upfront Payment to Acquire Finance Receivables Upfront Payment to Acquire Finance Receivables Accounts payable and accrued liabilities Business Combination, Recognized Liability Assumed, Accounts Payable and Accrued Liabilities Business Combination, Recognized Liability Assumed, Accounts Payable and Accrued Liabilities Revision of Prior Period, Accounting Standards Update, Adjustment Revision of Prior Period, Accounting Standards Update, Adjustment [Member] Research and Development Funding Expense Research And Development [Text Block] Research And Development Deferred stock, issued (in shares) Deferred Shares, Shares, Issued Deferred Shares, Shares, Issued Payments for Employee EPAs Payments for Employee Equity Performance Awards Payments for Employee Equity Performance Awards Individual licensees exceeding 10% or more of revenue (as percent) Concentration Risk, Percentage Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Equity Awards Adjustments Equity Awards Adjustments [Member] $600,000, 4.45% (issued at 98.909% of par) Four Point Four Five Percent Senior Notes Due 2031 [Member] Four Point Four Five Percent Senior Notes Due 2031 Total liabilities and shareholders’ equity Liabilities and Equity Other royalty cash collections Proceeds From Cash Collections From Other Royalties Received On Financing Receivables Proceeds From Cash Collections From Other Royalties Received On Financing Receivables Interest income Interest Income, Other Number of additional funding tranches Debt Securities, Available-For-Sale, Number Of Additional Funding Tranches Debt Securities, Available-For-Sale, Number Of Additional Funding Tranches Employee Stock Option Share-Based Payment Arrangement, Option [Member] Imdelltra Imdelltra [Member] Imdelltra Purchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases Non-controlling interests Equity, Attributable to Noncontrolling Interest Other liabilities Increase (Decrease) in Other Operating Liabilities Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Asset Class [Axis] Asset Class [Axis] Related Party [Domain] Related and Nonrelated Parties [Domain] Plan Name [Axis] Plan Name [Axis] Summary of Financial Royalty Assets, Net Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Tabular List, Table Tabular List [Table Text Block] Additional paid-in capital Additional Paid in Capital Equity securities Equity Securities, FV-NI, Noncurrent 2021 Notes 2021 Notes [Member] 2021 Notes Other non-operating expenses, net Other Nonoperating Income (Expense) Income from financial royalty assets Increase (Decrease) In Financial Royalty Assets Increase (Decrease) In Financial Royalty Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] General and administrative expenses (includes $107,356 and $91,044 of share-based compensation expense for the three months ended June 30, 2026 and 2025, respectively, and $229,648 and $91,747 for the six months ended June 30, 2026 and 2025, respectively; see Note 4) General and Administrative Expense Schedule of Research and Development Funding Expense Research and Development Arrangement, Contract to Perform for Others [Table Text Block] Measurement input Debt Instrument, Measurement Input Adjustment to Compensation: Adjustment to Compensation [Axis] $1,000,000, 2.20% (issued at 97.760% of par) Two Point Two Zero Percent Senior Notes Due 2030 [Member] Two Point Two Zero Percent Senior Notes Due 2030 Class of Stock [Domain] Class of Stock [Domain] Biogen Biogen [Member] Biogen Entities Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activity Statement of Cash Flows [Abstract] Other commitment Other Commitment 2025 Notes 2025 Notes [Member] 2025 Notes Employees With Award Participation Prior To Internalization Employees With Award Participation Prior To Internalization [Member] Employees With Award Participation Prior To Internalization Credit Facility [Axis] Credit Facility [Axis] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount The Legacy SLP Interest Legacy SLP Interest [Member] Legacy SLP Interest Cytokinetics Funding Commitment Cytokinetics Funding Commitment [Member] Cytokinetics Funding Commitment Name Measure Name Pay vs Performance Disclosure [Line Items] Other Other Noncash Income (Expense) Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Equity Performance Awards Equity Performance Awards [Member] Equity Performance Awards Unpaid amount expected to be settled in shares Equity Performance Award, Payable Equity Performance Award, Payable Share-based compensation and share issuances for EPAs, Equity Incentive Plans and forfeiture of shares issued for Internalization (in shares) Stock Issued During Period, Shares, Employee Benefit Plan Other current assets Increase (Decrease) in Other Current Assets Debt Instrument [Line Items] Debt Instrument [Line Items] Number of classes of stock Number Of Classes Of Voting Stock Number Of Classes Of Voting Stock Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Commercial Launch Funding Commercial Launch Funding [Member] Commercial Launch Funding Total purchase price Business Combination, Consideration Transferred Additional Paid-in Capital Additional Paid-in Capital [Member] Entity Filer Category Entity Filer Category Supplemental Cash Flow Elements [Abstract] Redemptions, asset Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions Federal Funds Rate Federal Funds Purchased [Member] Revision of Prior Period [Axis] Revision of Prior Period [Axis] Name Trading Arrangement, Individual Name Cash and cash equivalents Cash and Cash Equivalent Long Term Funding Partnership, Tranche [Domain] Long Term Funding Partnership, Tranche [Domain] Long Term Funding Partnership, Tranche [Domain] Litifilimab Litifilimab [Member] Litifilimab Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Company Selected Measure Amount Company Selected Measure Amount Interest payable Business Combination, Recognized Liability Assumed, Interest payable Business Combination, Recognized Liability Assumed, Interest Payable Distributions from equity method investees Distributions from equity method investees Proceeds from Equity Method Investment, Distribution (Gains)/losses on equity securities (Gains)/losses on equity securities Equity Securities, FV-NI, Unrealized Gain (Loss) Equity Method Investments and Joint Ventures [Abstract] Investments, Debt and Equity Securities [Abstract] Operating and Personnel Payments Operating And Personnel Payments [Member] Operating And Personnel Payments Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Accounts and Financing Receivables [Table] Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Consolidated net income Net income Net income Consolidated net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Employee Equity Performance Awards Employee Equity Performance Awards [Member] Employee Equity Performance Awards Other royalty income receivable Other Royalty Income Receivable, Current Other Royalty Income Receivable, Current Current assets Assets, Current [Abstract] Pro forma revenue Business Combination, Pro Forma Information, Pro Forma Revenue Non-PEO NEO Non-PEO NEO [Member] Entity Address, Address Line One Entity Address, Address Line One Income tax expense Income Tax Expense (Benefit) Tremfya Tremfya [Member] Tremfya Customer Concentration Risk Customer Concentration Risk [Member] Award Timing Method Award Timing Method [Text Block] Basis of Consolidation Consolidation, Policy [Policy Text Block] Net change in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Term Loan Term Loan [Member] Term Loan Less: Cumulative allowance for credit losses (Note 9) Financing Receivable, Allowance For Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal) Financing Receivable, Allowance For Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal) Total current assets Assets, Fair Value Disclosure, Current Assets, Fair Value Disclosure, Current EPAs earned Total EPAs Earned Total EPAs Earned Net income attributable to Royalty Pharma plc Net Income (Loss) Attributable to Parent Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Teva Pharmaceuticals Teva Pharmaceuticals [Member] Teva Pharmaceuticals Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Legacy Investors Partnerships Payable to Legacy Investors Partnerships Legacy Investors Partnerships [Member] Legacy Investors Partnerships Statement [Table] Statement [Table] Financing Receivable, Past Due [Table] Financing Receivable, Past Due [Table] Restatement Determination Date: Restatement Determination Date [Axis] Payments for operating and professional costs Payments For Operating Costs And Professional Services Payments For Operating Costs And Professional Services $1,000,000, 3.30% (issued at 95.556% of par) Three Point Three Zero Percent Senior Notes Due 2040 [Member] Three Point Three Zero Percent Senior Notes Due 2040 Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Phase 3, TEV-408 Phase 3, TEV-408 [Member] Phase 3, TEV-408 Tazverik Tazverik [Member] Tazverik Royalty Purchase Royalty Purchase [Member] Royalty Purchase Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Add: Reallocation of net income attributable from the assumed exchanges of Class B ordinary shares Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities Accounting Standards Update 2025-12 [Member] Accounting Standards Update 2025-12 Accounting Standards Update 2025-07 [Member]